[New possibilities in the treatment of Stargardt disease]

Area of Science:

• Ophthalmology
• Genetics
• Retinal Diseases

Background:

• Stargardt disease is an inherited retinal dystrophy caused by mutations in the ABCA4 gene.
• Current therapeutic options for Stargardt disease are limited, with no treatments having fully completed clinical trials.

Purpose of the Study:

• To review experimental and clinical studies on potential treatments for Stargardt disease.
• To summarize novel therapeutic strategies targeting the underlying mechanisms of the disease.

Main Methods:

• Review of experimental and clinical studies on Stargardt disease treatments.
• Analysis of therapeutic approaches including reducing vitamin A dimers, inhibiting complement, stem cell transplantation for RPE regeneration, and gene therapy.

Main Results:

• Various therapeutic strategies are under investigation, showing promise in preclinical and early clinical stages.
• Approaches include targeting toxic byproducts, modulating immune responses, cell-based therapies, and gene replacement.

Conclusions:

• Emerging treatments for Stargardt disease show potential but require further clinical validation.
• Gene therapy and stem cell transplantation represent promising avenues for future Stargardt disease management.